In an Unusual Move, FDA Reopens Comment Period on BE guidance for Sucralfate Suspension
While the FDA does appear to listen rather intently to comments on its bioequivalence (BE) draft guidances, and will occasionally reopen comment periods, it is still the exception rather than the rule. Today a Federal Register (FR) notice (here) announced another sixty-day comment period during which such comments will be entertained. The FR notice explains […]
